A new study indicates.

Oncologists can use this given information, in combination with other diagnostic exams and clinical options for monitoring metastatic breast cancers, to assess a patient's overall prognosis and help predict progression free survival and general survival. Liu, M.D., of the medical molecular diagnostics laboratory at Georgetown University's Lombardi Comprehensive Cancer Middle and a key investigator in the CTC research.D., Head of Technology Technology at Veridex.We believe they possess the potential to improve patient comfort and protection, surgical team fulfillment and efficiency, and enhance returns for health care institutions. OPKO shall perform additional research required for regulatory authorization and commercial use. Phillip Frost, M.D. The good thing is that the real number of new cases of breast cancer dropped from 1999 to 2005, which may be because of the reduction in the usage of hormone replacement therapy.

Comments are closed.